Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
To identify the path to innovation, in harmony with life
Life is constantly adapting to new conditions. It innovates to keep going. We put our intelligence at your service to guide you towards success. Oncodesign’s culture is based on sharing, mutual assistance, community, sociability and, more generally, solidarity.
Creation by its CEO and founder Philippe Genne, in Dijon, as a pharmacology services company to select the best oncology drug candidates.
Foundation by Oncodesign of a regional center of excellence in pharmaco-imaging to monitor the effect of therapies and identify translational efficacy biomarkers for precision medicine. Pharmimage brings together hospitals, biotechnology and pharmaceutical companies in Dijon, France.